Enanta Pharmaceuticals ( ENTA ) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. ( CERT ) Reports Next Week: Wall Street Expects Earnings Growth
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection - Enanta Pharma ( NASDAQ:ENTA ) , AbbVie ( NYSE:ABBV )
Mavyret approved for acute HCV in patients aged 3+ with or without cirrhosis. Eight-week treatment shows 96% cure rate with mostly mild side effects. Ready to turn the market's comeback into steady cash flow? Grab the top 3 stocks to buy right here. The U.S.
Does Enanta Pharmaceuticals ( ENTA ) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Enanta Pharmaceuticals ( ENTA ) Reports Q2 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -1.92% and 8.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical ( PROF ) Reports Q1 Loss, Misses Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of -24.14% and 24.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals ( IONS ) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.43% and 9.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals ( ENTA ) Moves to Buy: Rationale Behind the Upgrade
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals ( ENTA ) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals ( RXRX ) Moves 8.9% Higher: Will This Strength Last?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
United Airlines To Rally More Than 20%? Here Are Top Analyst Forecasts For Monday - Applied Optoelectronics ( NASDAQ:AAOI ) , Allegiant Travel ( NASDAQ:ALGT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Northland Capital Markets cut the price target for Applied Optoelectronics, Inc. AAOI from $20 to $18.
CrowdStrike To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Berkshire Hills Bancorp ( NYSE:BHLB ) , Brixmor Property Group ( NYSE:BRX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. DA Davidson cut Winnebago Industries, Inc. WGO price target from $55 to $54.
Enanta Pharmaceuticals ( ENTA ) Moves 7.2% Higher: Will This Strength Last?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Enanta Pharmaceuticals ( ENTA ) Reports Q4 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -17.24% and 20.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
60 Degrees Pharmaceuticals Inc. ( SXTP ) Reports Q3 Loss, Misses Revenue Estimates
60 Degrees Pharmaceuticals Inc. (SXTP) delivered earnings and revenue surprises of -55% and 60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ElectroCore, Inc. ( ECOR ) Reports Q3 Loss, Tops Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of -6.90% and 1.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation ( DERM ) Reports Q3 Loss, Tops Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of 29.41% and 1.87%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals ( ENTA ) Surges 5.6%: Is This an Indication of Further Gains?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Enanta Pharmaceuticals Reports Antiviral For Respiratory Syncytial Virus Reduces Virus Levels, Symptoms In Study - Enanta Pharma ( NASDAQ:ENTA )
Enanta Pharmaceuticals Inc. ENTA released on Thursday topline results from a Phase 2a human challenge study of EDP-323 in healthy adults infected with respiratory syncytial virus ( RSV ) .
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer - Xenon Pharmaceuticals ( NASDAQ:XENE )
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. XENE, a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of ...
Enanta Pharmaceuticals ( ENTA ) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 28.19% and 3.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals ( ENTA ) Soars 6.7%: Is Further Upside Left in the Stock?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Stock Rating Upgraded by StockNews.com
Enanta Pharmaceuticals ( NASDAQ:ENTA - Get Free Report ) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Wednesday. ENTA has been the subject of several other reports.
Enanta Pharmaceuticals ( ENTA ) Reports Q2 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -16.67% and 3.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
StockNews.com Downgrades Enanta Pharmaceuticals ( NASDAQ:ENTA ) to Sell
Enanta Pharmaceuticals ( NASDAQ:ENTA - Get Free Report ) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Saturday.
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Lifted to Hold at StockNews.com
StockNews.com upgraded shares of Enanta Pharmaceuticals ( NASDAQ:ENTA - Free Report ) from a sell rating to a hold rating in a research report report published on Friday morning.
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Downgraded to Sell at StockNews.com
StockNews.com cut shares of Enanta Pharmaceuticals ( NASDAQ:ENTA - Free Report ) from a hold rating to a sell rating in a research note issued to investors on Thursday. Other equities research analysts also recently issued reports about the company.
Enanta Pharmaceuticals ( ENTA ) Reports Q1 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key ... PR ...
Strength Seen in Enanta Pharmaceuticals ( ENTA ) : Can Its 13.8% Jump Turn into More Strength?
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World
Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog.
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Lifted to Hold at StockNews.com
StockNews.com upgraded shares of Enanta Pharmaceuticals ( NASDAQ:ENTA - Free Report ) from a sell rating to a hold rating in a research report report published on Tuesday morning.
5 Secret Santa Stocks to Pop Surprise Returns
Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.
Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals ( ENTA ) : Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 108.1% in Enanta Pharmaceuticals (ENTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
How Much Upside is Left in Enanta Pharmaceuticals ( ENTA ) ? Wall Street Analysts Think 88.23%
The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Analysts Estimate Enanta Pharmaceuticals ( ENTA ) to Report a Decline in Earnings: What to Look Out for
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences, Inc. ( ALPN ) Surges 8.9%: Is This an Indication of Further Gains?
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Rating Lowered to Sell at StockNews.com
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Rating Lowered to Sell at ... Defense World ...
Enanta Pharmaceuticals Downgraded to Sell Rating by StockNews.com
Enanta Pharmaceuticals Downgraded to Sell Rating by StockNews ... Clayton County Register ...
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Upgraded to Hold at StockNews.com
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Upgraded to Hold at ... Defense World ...
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
Airbnb ( ABNB ) and Blackstone ( BX ) will join the S&P 500 before the open on Sept. 18, part of a quarterly rebalance for S&P Indices. ABNB stock and Blackstone rose Friday night on the news.
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Lowered to Sell at StockNews.com
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Lowered to Sell at ... Defense World ...
Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600
Blackstone and Airbnb Set to Join S&P 500. Others to Join S&P 100, S&P MidCap 400 and ...
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Rating Increased to Hold at StockNews.com
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Rating Increased to Hold ... Defense World ...
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday - Axsome Therapeutics ( NASDAQ:AXSM ) , Biogen ( NASDAQ:BIIB )
Piper Sandler raised the price target for Chegg, Inc. CHGG from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market trading. Atlantic Equities cut Biogen Inc. BIIB price target from $282 to $275.
Enanta Pharmaceuticals ( ENTA ) Reports Q3 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 21.85% and 19.01%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Enanta Pharmaceuticals ( ENTA ) Stock?
Investors need to pay close attention to Enanta Pharmaceuticals (ENTA) stock based on the movements in the options market lately.
Why Enanta ( ENTA ) Shares Are Plunging Today - Enanta Pharma ( NASDAQ:ENTA )
Enanta Pharmaceuticals Inc's ENTA investigational COVID-19 pill, EDP-235, met its primary endpoints of safety and tolerability in its Phase 2 SPRINT trial but yielded mixed results on its effectiveness.
Gold Edges Higher; PayPal Shares Tumble Despite Upbeat Earnings - Coherus BioSciences ( NASDAQ:CHRS ) , ClearOne ( NASDAQ:CLRO )
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 50 points on Tuesday. The Dow traded down 0.01% to 33,616.00 while the NASDAQ fell 0.43% to 12,204.79. The S&P 500, also fell, dropping, 0.24% to 4,128.12. Energy shares rose by 0.3% on Tuesday.
